Investors sold shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) on strength during trading on Monday. $37.11 million flowed into the stock on the tick-up and $80.12 million flowed out of the stock on the tick-down, for a money net flow of $43.01 million out of the stock. Of all stocks tracked, Alexion Pharmaceuticals had the 0th highest net out-flow for the day. Alexion Pharmaceuticals traded up $0.88 for the day and closed at $125.30

Several research firms recently commented on ALXN. Cowen and Company restated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, April 17th. Jefferies Group restated a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, May 29th. Piper Jaffray Cos. restated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Sunday, June 26th. Credit Suisse Group AG reiterated a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Saturday. Finally, Leerink Swann reiterated a “buy” rating and set a $216.00 price objective (down from $217.00) on shares of Alexion Pharmaceuticals in a research note on Saturday, March 19th. Seven investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $192.07.

The firm’s 50 day moving average is $132.31 and its 200-day moving average is $144.67. The company has a market capitalization of $28.07 billion and a P/E ratio of 189.56.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $1.11 EPS for the quarter, missing the consensus estimate of $1.13 by $0.02. During the same quarter in the previous year, the business earned $1.28 earnings per share. The company earned $701 million during the quarter, compared to the consensus estimate of $710.98 million. Alexion Pharmaceuticals’s revenue was up 16.8% compared to the same quarter last year. Equities research analysts expect that Alexion Pharmaceuticals Inc. will post $5.05 earnings per share for the current fiscal year.

In related news, EVP John B. Moriarty sold 918 shares of the stock in a transaction on Monday, June 13th. The stock was sold at an average price of $135.72, for a total transaction of $124,590.96. Following the sale, the executive vice president now directly owns 51,360 shares of the company’s stock, valued at $6,970,579.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Martin Mackay sold 4,097 shares of the stock in a transaction on Monday, May 16th. The shares were sold at an average price of $139.20, for a total value of $570,302.40. Following the sale, the executive vice president now directly owns 42,706 shares in the company, valued at $5,944,675.20. The disclosure for this sale can be found here.

Other large investors have added to or reduced their stakes in the company. LS Investment Advisors LLC boosted its stake in Alexion Pharmaceuticals by 1.7% in the fourth quarter. LS Investment Advisors LLC now owns 5,257 shares of the biopharmaceutical company’s stock valued at $1,003,000 after buying an additional 89 shares during the period. CG Asset Management LLC boosted its position in shares of Alexion Pharmaceuticals by 19.5% in the fourth quarter. CG Asset Management LLC now owns 6,750 shares of the biopharmaceutical company’s stock valued at $1,288,000 after buying an additional 1,100 shares during the last quarter. Sawtooth Asset Management Inc. boosted its position in shares of Alexion Pharmaceuticals by 15,072.9% in the fourth quarter. Sawtooth Asset Management Inc. now owns 7,283 shares of the biopharmaceutical company’s stock valued at $1,389,000 after buying an additional 7,235 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its position in shares of Alexion Pharmaceuticals by 18.9% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 9,909 shares of the biopharmaceutical company’s stock valued at $1,890,000 after buying an additional 1,574 shares during the last quarter. Finally, Wetherby Asset Management Inc. boosted its position in shares of Alexion Pharmaceuticals by 0.5% in the fourth quarter. Wetherby Asset Management Inc. now owns 10,211 shares of the biopharmaceutical company’s stock valued at $1,948,000 after buying an additional 49 shares during the last quarter.

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.